Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

计划入组 647 人 · 首次发布于 2024 年 9 月 19 日

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

计划入组 37 人 · 首次发布于 2024 年 2 月 7 日

A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids

计划入组 40 人 · 首次发布于 2010 年 3 月 25 日

OR-2100

PS-2100

RCT-2100

Pharma 2100 ApS

Denmark

1200 Pharma LLC

United States

SLATE PHARMACEUTICALS INC

United States

Fulcrum and Slate Medicines to Combine in Reverse Merger, Advancing Next-Generation Migraine Therapies

Recode Therapeutics' RCT-2100 Shows Promise for Cystic Fibrosis Treatment

Slate Medicines Secures $130M Series A to Advance Novel Anti-PACAP Migraine Therapy